Please refer attachment.

1st October, 2026 BSE Limited P.J. Towers, Dalal Street, Fort, Mumbai- 400 001 BSE scrip code: 543635 Kind Attention: Mr. Sagar Darra Sub: Clarification on news item which appeared in the “www.thehindubusinessline.com” dated September 30, 2026 captioned “Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma’s Aurora Facility.” This is with reference to your email dated September 30, 2026 seeking clarification on the news item titled Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility. In this regard, we wish to clarify that the news item pertains to funding support received by the Company's Aurora facility from the Government of Ontario under the Life Sciences Scale-Up Fund (LSSUF) program, which aims to support innovative Ontario-based life sciences companies in scaling their operations and responding to procurement opportunities. The funding is intended to support infrastructure upgrades, site modernization, operational efficiency, sustainability initiatives, and other enhancement projects at the Aurora facility. The project is also expected to contribute to employment generation and retention, support innovation and commercialization initiatives, and strengthen the broader life sciences and biomanufacturing ecosystem in Ontario. The funding support does not constitute a material event or information requiring disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as it is not expected to have a material impact on the Company's operations, financial position, or performance. Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla, Mumbai - 400070 T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com www.piramalpharma.com We further clarify that the movement in the price and/or volume of the shares of the Company, if any, appears to be driven by market dynamics. The Company is not aware of any specific reason or information that may have resulted in such movement. Kindly take the above clarification on record. Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla, Mumbai - 400070 T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com www.piramalpharma.com